A pharmacokinetic analysis of molecular cardiac surgery with recirculation mediated delivery of βARKct gene therapy: Developing a quantitative definition of the therapeutic window

Journal of Cardiac Failure

Volumn 17, Issue 8, 2011, Pages 691-699

  Fargnoli, Anthony S ^a   Katz, Michael G ^a   Yarnall, Charles ^a   Sumaroka, Marina V ^a   Stedman, Hansell ^a   Rabinowitz, Joseph J ^b   Koch, Walter J ^b   Bridges, Charles R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

beta adrenergic signaling system; Cardiac gene therapy; cardiac surgery; gene pharmacokinetics

Indexed keywords

ADENOVIRUS VECTOR; BETA ADRENERGIC RECEPTOR KINASE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CLEARANCE; DRUG EXPOSURE; DRUG HALF LIFE; FEMALE; GENE THERAPY; GENOME; HUMAN; IN VIVO GENE TRANSFER; MAJOR CLINICAL STUDY; MALE; MOLECULAR CARDIAC SURGERY WITH RECIRCULATING DELIVERY; PHARMACOKINETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SEROTYPE; VIRUS RECOMBINANT; WESTERN BLOTTING;

ANIMALS; CARDIAC SURGICAL PROCEDURES; CORONARY CIRCULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; PEPTIDES; RECOMBINANT PROTEINS; SHEEP; TISSUE DISTRIBUTION;

EID: 79961002679     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2011.03.011     Document Type: Article

References (20)

1. Katz MG, Swain JD, Tomasulo CE, Sumaroka M, Fargnoli A, Bridges CR. Current strategies for myocardial gene delivery. J Mol Cell Cardiol 2011;50:766-76.
2. Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE, Koch WJ. Myocardial adeno-associated virus serotype 6-βARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 2009;119:89-98.
3. Rengo G, Lymperopoulos A, Leosco D, Koch WJ. GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol 2011;50:785-92.
4. Zincarelli C, Soltys S, Rengo G, Koch WJ, Rabinowitz JE. Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. Clin Transl Sci 2010;3:81-9.
5. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg BJ, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID trial), a first-in-human phase 1/2 clinical trial. J Cardiac Fail 2009;15:171-81.
6. Donahue JK, Kikkawa K, Johns DC, Marban E, Lawrence JH. Ultrarapid, highly efficient viral gene transfer to the heart. Proc Natl Acad Sci U S A 1997;94:4664-8. (Pubitemid 27194300)
7. Logeart D, Hatem SN, Heimburger M, Le Roux A, Michel JB, Mercadier JJ. How to optimize in vivo gene transfer to cardiac myocytes: mechanical or pharmacological procedures? Hum Gene Ther 2001;12:1601-10.
8. Kaplitt MG, Xiao X, Samulski RJ, Li J, Ojamaa K, Klein IL, et al. Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector. Ann Thorac Surg 1996;62:1669-76. (Pubitemid 26421099)
9. Raake P, Degenfeld G, Hinkel R, Vachenauer R, Sandner T, Beller S, et al. Myocardial gene transfer by selective pressure regulated-retroinfusion of coronary veins: comparison with surgical and percutaneous intramyocardial gene delivery. JAm Coll Cardiol 2004;44:1124-9. (Pubitemid 39165150)
10. Bridges CR. "Recirculating cardiac delivery" method of gene delivery should be called "nonrecirculating" method. Gene Ther 2009;16:939-40.
11. Katz MG, Swain JD, Fargnoli A, Bridges CR. Gene therapy during cardiac surgery: role of surgical technique to minimize collateral organ gene expression. Interact Cardiovasc Thorac Surg 2010;11:727-31.
12. Bridges CR, Gopal K, Holt DE, Yarnall C, Cole S, Anderson RB, et al. Efficient myocyte gene delivery with complete cardiac surgical isolation in situ. J Thorac Cardiovasc Surg 2005;130:1364.e1-e8.
13. White JD, Thesier DM, Swain JB, Katz MG, Tomasulo C, Henderson A, et al. Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo. Gene Ther 2011 Jan 13. [Epub ahead of print].
14. Jones M, Wilson KH, Steenbergen C, Koch WJ, Milano CA. Dose dependent effects of cardiac b2 adrenoreceptor gene therapy. J Surgical Research 2004;122:113-20. (Pubitemid 39441241)
15. Pleger ST, Boucher M, Most P, Koch WJ. Targeting myocardial beta-adrenergic receptor signaling and calcium cycling for heart failure gene therapy. [review]. J Card Fail 2007;13:401-14. (Pubitemid 46977786)
16. Boekstegers P, von Degenfeld G, Giehrl W, Kupatt C, Franz W, Steinbeck G. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther 2000;7:232-40. (Pubitemid 30113772)
17. Grossman PM, Han Z, Palasis M, Barry JJ, Lederman RJ. Incomplete retention after direct myocardial injection. Catheter Cardiovasc Interv 2002;55:392-7. (Pubitemid 34204886)
18. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006;14:316-27. (Pubitemid 44184972)
19. Greelish JP, Su LT, Lankford EB, Burkman JM, Chen H, Konig SK, et al. Stable restoration of the sarcoglycan complex in dystrophic-muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med 1999;5:439-43. (Pubitemid 29180585)
20. Halbert CL, Allen JM, Miller AD. Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol 2001;75:6615-24. (Pubitemid 32578181)